|1.||Habr, Dany: 25 articles (09/2015 - 06/2009)|
|2.||Porter, John B: 22 articles (09/2015 - 10/2006)|
|3.||Cappellini, Maria Domenica: 21 articles (03/2015 - 05/2006)|
|4.||Piga, Antonio: 17 articles (09/2015 - 06/2003)|
|5.||Galanello, Renzo: 16 articles (11/2013 - 06/2003)|
|6.||Kattamis, Antonis: 15 articles (06/2015 - 05/2006)|
|7.||Forni, Gian Luca: 13 articles (04/2015 - 07/2006)|
|8.||Porter, John: 13 articles (02/2013 - 05/2006)|
|9.||Taher, Ali: 12 articles (06/2014 - 01/2009)|
|10.||Vichinsky, Elliott: 12 articles (12/2013 - 02/2007)|
01/01/2012 - "We report two patients who achieved a marked improvement of hematopoiesis with the use of deferasirox (DSX) for transfusional iron overload. "
12/01/2013 - "Efficacy of Deferasirox for the treatment of iron overload in Chinese thalassaemia major patients: results from a prospective, open-label, multicentre clinical trial."
05/01/2012 - "In conclusion, our data suggest that oral deferasirox treatment may be used as a safe and effective alternative method for reducing iron overload in alloHSCT recipients, whether combined with or without phlebotomy."
06/01/2010 - "Although the number of subjects is small, deferasirox may be a safe and effective alternative for allogeneic HCT survivors with iron overload who cannot undergo phlebotomy."
07/01/2013 - "In this review, we report the results of different studies testing safety and efficacy of deferasirox in MDS patients, side effects associated with the drug, and suggested management of iron overload."
|2.||beta-Thalassemia (Cooley's Anemia)
06/01/2012 - "Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major."
05/01/2006 - "A comparative phase 3 trial was conducted to demonstrate the efficacy of deferasirox in regularly transfused patients with beta-thalassemia aged 2 years or older. "
01/01/2012 - "Efficacy of deferasirox in North Indian β-thalassemia major patients: a preliminary report."
03/01/2013 - "This study aimed to estimate the incidence of deferasirox (DFX) side effects in patients with thalassemia major or intermedia. "
04/15/2012 - "The method can be used to support a wide range of clinical studies concerning deferasirox monitoring and it was applied to the analysis of human plasma samples obtained from patients with β-thalassemia major."
08/01/2014 - "Efficacy of deferasirox in children with β-thalassemia: single-center 3 year experience."
01/01/2012 - "HRQOL improved following treatment with deferasirox, particularly among β-thalassemia patients. "
10/01/2011 - "Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years."
03/01/2011 - "Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent β-thalassemia."
12/01/2015 - "The aim of this study was to evaluate the long-term efficacy and tolerability of deferasirox in Taiwanese patients with transfusion-dependent β-thalassemia who have been treated with deferasirox for 7 years. "
|4.||Myelodysplastic Syndromes (Myelodysplastic Syndrome)
04/01/2013 - "Safety and efficacy of deferasirox in the management of transfusion-dependent patients with myelodysplastic syndrome and aplastic anaemia: a perspective review."
09/01/2012 - "This analysis suggests that deferasirox treatment for up to 1 year could lead to improvement in hematologic parameters in some patients with myelodysplastic syndromes."
06/10/2012 - "This 3-year, prospective, multicenter trial assessed the safety and efficacy of deferasirox in low- or intermediate-1-risk myelodysplastic syndrome (MDS). "
06/01/2014 - "Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial)."
04/01/2015 - "A case of transfusion independence in a patient with myelodysplastic syndrome using deferasirox, sustained for two years after stopping therapy."
01/01/2013 - "Here, we describe the case of a 73-year-old man affected by PMF and severe transfusion-dependent anemia who experienced a dramatic erythroid response after being treated with deferasirox to prevent IOL. "
01/01/2009 - "Cumulative data from prospective studies in over 3,000 patients with a range of transfusion dependent anemias have established key principles about the efficacy and safety of deferasirox (DFS). "
06/01/2007 - "The efficacy and safety of deferasirox have been established in a comprehensive clinical development program involving patients with various transfusion-dependent anemias. "
09/23/2015 - "Acute Liver Failure in a Pediatric Patient with Congenital Dysery-Thropoietic Anemia Type I Treated with Deferasirox."
04/01/2015 - "We analyzed deferasirox plasma concentrations (CDFX ) in 80 patients with transfusion-dependent anemias, such as thalassemia, by a high performance liquid chromatography (HPLC) assay. "
|5.||liposomal amphotericin B
|10.||Iron Chelating Agents
|1.||Chelation Therapy (Therapy, Chelation)
|2.||Drug Therapy (Chemotherapy)
|3.||Blood Transfusion (Blood Transfusions)
|4.||Transplantation (Transplant Recipients)